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Abstract 
Aim: Inhaled racemic adrenaline was used for bronchiolitis in many hospitals in Finland prior to 
new national current care guidelines for bronchiolitis in 2014, which limited its recommendations to 
on-demand rescue therapy. We studied the drug’s use before and after the new guidelines to 
gauge changes in prescribing habits. 
Methods: This 2012-2016 study analysed how many 0.5 ml doses of racemic adrenaline were 
used for children by emergency rooms, paediatric wards and paediatric intensive care units at four 
university hospitals and estimated drug and staff costs.   
Results: There were substantial differences in the yearly consumption of racemic adrenaline 
between the hospitals before and after the bronchiolitis guidelines were published, with reductions 
in drug costs and staff time. The overall use more than halved during the study period, particularly 
in two hospitals where baseline consumptions were highest, but not in a third where baseline 
consumption was already low. In the fourth, the baseline consumption was modest and there was 
a constant decrease during the study years.   
Conclusion: The current care guidelines for bronchiolitis had some impact on clinical practice as 
the overall use of racemic adrenaline more than halved, but considerable differences remained in 
the four study hospitals after their publication.  
Key notes 
• We examined the use of racemic adrenaline in four Finnish university hospitals from 2012-
2016, before and after 2014 when national current care guidelines on bronchiolitis limited
its recommendations to on-demand rescue therapy.
• The overall use of racemic adrenaline more than halved, suggesting that the guidelines had
an impact on clinical practice.
• However, we continued to find differences in its use between the hospitals before and after
the guidelines were published.
Key words: bronchiolitis, clinical guidelines, prescribing patterns, racemic adrenaline, rescue 
therapy. 
INTRODUCTION 
Acute bronchiolitis is a common respiratory disease in infancy and in Nordic countries it is defined 
as the first episode of respiratory distress, with or without wheezing, before the age of 12 months 
(1). In contrast, the guidelines issued by the American Academy of Pediatrics in 2006 (2) and the 
UK’s National Institute for Health and Care Excellence in 2015 (3) are based on an upper age limit 
of 24 months. The incidence of bronchiolitis is high in children under the age of one, with one in 
three  presenting with mild-to-moderate bronchiolitis and 1-3% with severe bronchiolitis being 
treated in hospital (2,4). 
The treatment of acute bronchiolitis has included inhalations of hypertonic saline, racemic 
adrenaline or salbutamol, inhaled or systemic corticosteroids and repeated suctioning of the 
airways. However, none of these interventions have proved to be effective (5-7) and none of the 
current guidelines on managing bronchiolitis recommend routine use of bronchodilators or 
corticosteroids (2,3). Cleaning the airways with suctioning is only useful if there is a lot of mucus in 
the respiratory tract and is not recommended when there is just mucosal swelling. Some research-
based evidence has been published that suggests that inhaling racemic adrenaline may be useful 
in selected patients with bronchiolitis (8), but mainly as a rescue therapy (9). The cornerstones of 
the treatment for bronchiolitis are still monitoring breathing and feeding, and supplementary 
oxygen and fluid and ventilator support if needed. 
In the summer of 2014, national evidence-based current care guidelines for treating infant 
bronchiolitis and other lower respiratory tract infections in children were published in Finland (10). 
These guidelines did not recommend the use of racemic adrenaline for the routine treatment of 
acute bronchiolitis, but stated that it could be used as an on-demand rescue therapy. 
In children`s hospitals, the only common indication for the use of racemic adrenaline in recent 
years has been acute bronchiolitis (1). Other less common uses have included treating acute 
laryngitis, acute severe asthma and as a rescue therapy for laryngeal spasms during, or after, 
intubation. 
Although different evidence-based guidelines are now being published more frequently in many 
countries, their effectiveness has been insufficiently studied (11). However, a 2017 study reported 
that the implementation of the UK bronchiolitis guidelines, which were published by the National 
Institute for Health and Care Excellence in 2015 and supported by a simple educational 
intervention, reduced the number of chest radiographs and antibiotics prescribed for bronchiolitis 
(12). In the USA, the publication of the 2006 American Academy of Pediatrics bronchiolitis 
guidelines was associated with reductions in the use of resources, including chest radiographies, 
bronchodilators and corticosteroids (13).  
The aim of this study was to evaluate the impact of the 2014 Finnish evidence-based current care 
guidelines on the treatment of bronchiolitis in four university hospitals in Finland. The consumption 
of racemic adrenaline was assessed each year from 2012 to 2016, before and after publication of 
the national guideline on the treatment of bronchiolitis in 2014. 
MATERIAL AND METHODS 
This study evaluated the consumption of racemic adrenaline in the paediatric departments of four 
Finnish University Hospitals - Kuopio, Oulu, Tampere and Turku – by using hospital pharmacy 
records. We estimated the consumption based on the numbers of doses of racemic adrenaline 
(racepinephrine 2.25% 0.5 ml) that the hospital pharmacies delivered to the paediatric departments 
of the hospitals. As well as analysing total consumption, we obtained detailed information on the 
amount used by the different paediatric units, such as the paediatric emergency room, the 
paediatric infectious disease ward and the paediatric intensive care unit (PICU).  
Cost data on the actual drugs were obtained from the pharmacy at Tampere University Hospital 
and we used other data from the hospital on associated factors, such as staff time. All the costs 
were evaluated using 2017 prices and were reported as Euros. The doses of racemic adrenaline 
cost €2.30 each. The nurses’ time was evaluated in hours and their salaries were not taken into 
account in the cost calculations. We estimated that it took 10 minutes to check the doctor’s order, 
prepare the drug and solution ready for use and give the nebulised drug to the infant. This time 
was under-estimated rather than over-estimated and any time taken to reassure the infant was not 
included, although it was often needed. 
The numbers of infants under the age of 12 months admitted for bronchiolitis to the paediatric 
emergency room of Tampere University Hospital were available from the hospital’s electronic files 
for 2013-2015 and they were 238 in 2013, 213 in 2014 and 172 in 2015. The bronchiolitis 
diagnoses were confirmed with revisiting the patient records. According to the national Register for 
Infectious Diseases, the total number of laboratory-confirmed respiratory syncytial virus  (RSV) 
infections in Finland was 4947 in 2016, compared to 1991, 2868 and 2436 in 2013, 2014 and 
2015, respectively (14). 
In addition we retrieved Government data on the number of children under 16 years of age 
covered by the four hospital districts and these were: Tampere (91,010), Oulu (88,094), Kuopio 
(26,518) and Turku (78,641) (15).  
The consumption of racemic adrenaline was expressed as crude numbers of consumed doses and 
as the number of consumed doses per 10,000 children aged less than 16 years in the population. 
RESULTS 
There were substantial differences in the yearly consumption of racemic adrenaline between the 
four university hospitals both before and after publishing of the bronchiolitis guideline (Table 1).  
There was also a significant decrease in the annual use of racemic adrenaline between 2012-2013 
and 2015-2016 in Kuopio and Tampere, but not in Oulu where the baseline consumption was 
already low (Table 1). In Turku, the baseline consumption was modest and there was a constant 
decrease during the study years (Figure S1). The highest consumption in 2012 was in Tampere 
(3,295), followed by Kuopio (2,283), Turku (1,135) and Oulu (468), but this had fallen by just over 
54% in 2016 and the order had changed to Kuopio (1,373), Tampere (773), Oulu (650) and Turku 
(326). When the rates were presented per 10,000 children under the age of 16 in 2012 and 2016, 
they were 846 and 734 in Kuopio, 366 and 85 in Tampere, 144 and 42 in Turku and 56 and 74 in 
Oulu.  The overall reduction in the use of racemic adrenal across the four hospitals during the 
study period was just over 54%. 
In 2012-2013, when the consumption of racemic adrenaline was common in Tampere and Kuopio, 
two-thirds of the consumption was in paediatric wards handling infection diseases. This was mainly 
due to the fact that the most common cause for hospitalisation was bronchiolitis and those patients 
were given racemic adrenaline inhalations. Although, the indications in the emergency room and 
PICU showed more variations, bronchiolitis was also the most common disease treated with 
racemic adrenaline. 
The numbers of children admitted to the emergency room of hospital for bronchiolitis were 
available from Tampere, and the numbers of doses delivered from the hospital pharmacy per an 
admitted child were 14.7 in 2013, 11.5 in 2014 and 4.5 in 2015.  In 2016, when there was a severe 
RSV epidemic in Finland, the total numbers of laboratory-confirmed RSV infections were 2.5-fold, 
1.7-fold and 2.0-fold higher than in 2013, in 2014 or in 2015, respectively.    
The annual medication costs tended to be stable in Oulu and Kuopio and decreased in Tampere 
and Turku, reflecting changes in their use of racemic adrenaline. In 2012, the annual costs varied 
from €7,579 to €1,116 and in 2016 they varied from €3,158 to €750 (Table 2). Another notable 
expense was the time that the nurses spent preparing the medicines and solutions ready for use 
and administering the nebulised medicines to the infants. In 2012, the annual working time varied 
from a total of 186 to 1,263 hours for the four hospitals and in 2016 it varied from 125 to 526 hours 
(Table 2). The largest decrease, of 967 hours or 25.3 working weeks, occurred in Tampere. Other 
expenses that should be taken into account, apart from the cost of each drug dose (€2.30), were 
the two needles and two syringes required for one dose of racemic adrenaline (total €0.15), 2mL of 
normal saline solution per dose (€0.03) and the pro-rata purchase price and servicing of the 
nebuliser (€2.38) for each dose. These repeated costs €2.48 per dose, depended on the number 
of racemic adrenaline doses that were used. In 2012, the repeated costs ranged from €1,193 to 
€8,106 and in 2016 they ranged from €802 to €3,378. 
DISCUSSION 
Racemic adrenaline inhalations have been widely used in the Nordic countries to treat bronchiolitis 
(1,9). The accumulating evidence against the routine use of adrenaline (2,9), meant that its use 
was not recommended for clinical practice when the Finnish evidence-based current care 
guidelines were published in 2014 (10). This study was conducted to evaluate the impact of these 
guidelines on clinical practice comparing the two years before and after their introduction. 
There were three key results that emerged from our study. First, the use of racemic adrenaline 
decreased substantially after the Finnish guidelines were published, based on the number of doses 
delivered by pharmacies to the departments in the four university hospitals. Second, although the 
use of racemic adrenaline fell after the guidelines were published, its use continued to vary 
considerably between the hospitals, especially with regard to the population-based analyses. 
Third, the medication costs were relatively modest, but time that the nurses spent administering 
racemic adrenaline showed a notable decrease. These results suggest that the evidence-based 
current care guidelines contributed to real-life treatment practice.  
In the present study, the greatest decrease in the consumption of racemic adrenaline was mainly 
seen, as expected, in the hospitals that used the greatest quantities before the guidelines were 
issued. In the USA, the overall consumption of bronchodilators in bronchiolitis decreased modestly, 
from 70% to 58% in 2008-2012, after the 2006 American Academy of Pediatrics guidelines on the 
management of bronchiolitis were published. However, the figures for racemic adrenaline were not 
given separately (16). In hospitalised children in the USA, the use of racemic adrenaline for 
bronchiolitis decreased from 17.8% in 2004-2005 to 12.2% in 2007-2008 (17). On the other hand, 
some reports concluded that the use of bronchodilators remained stable after implementation of 
the 2006 guidelines, both in ambulatory and hospital settings (18,19). A  study published in 2017, 
reported that, following the publication of the 2015 guidelines on managing bronchiolitis by the 
UK’s National Institute for Health and Care Excellence, a secondary paediatric unit in England 
performed an educational intervention and the use of salbutamol decreased from 36% to 24%. 
However, the authors pointed out that racemic adrenaline was not used by this hospital, either 
before or after 2015 (12). 
The use of racemic adrenaline varied a lot between the four university hospitals in our study. A 
study of three of the four Finnish university hospitals featured in the current study was carried out 
in 2008-2010, and substantial variation was observed in terms of other diagnostic and treatment 
practices for bronchiolitis, such as the use of salbutamol inhalations, systemic corticosteroids or 
intravenous versus oral fluid therapies (20). Notable variations that cannot be explained by disease 
severity or readmission rates, have been reported from the USA and Spain (19,21,22). 
Furthermore, the use of unnecessary treatment, such as bronchodilators, antibiotics and 
corticosteroids, has been associated with longer stays in hospital in the USA (19).  
 
A retrospective time series study from the USA revealed that, after the implementation of the 
American 2006 bronchiolitis guidelines, the average total costs per patient fell by $197 in the 
emergency room (23). This reduction was based on the decreased use of chest radiographs and 
tests for viruses, as well as reductions in the medication used. Our study identified reductions in 
the medication costs and the time spent by the nurses who prepared and gave the inhalations of 
racemic adrenaline. In Tampere, the nurses’ annual total working time decreased by 967 hours 
from 2012 to 2016, which was the equivalent of six months for one nurse working full time. The 
reduction meant that nurses were free to carry out other duties in these busy departments.   
 
The impact that evidenced-based guidelines and clinical practice guidelines have on everyday 
practice remains unclear (11,24). A prospective closed-loop audit study performed in the UK 
reported significant improvement in clinical practice after treatment guidelines were issued on the  
treatment of pneumonia (25). Meanwhile a multicentre voluntary collaboration of 21 American 
primarily community hospitals found that a web-based initiative that included data collection and 
feedback to doctors on bronchiolitis resulted in a 29% reduction in the use of bronchodilators, a 
68% reduction in the use of corticosteroids and a 44% reduction in chest radiography (26). In 
Finland, a limited number of doctors treat infants with bronchiolitis, which means that the 
implementation of the guidelines in the study hospitals was probably easier than in the case of 
many other illnesses or in other settings than hospitals with specific paediatric expertise. Our study 
showed that a certain level of harmonisation can be achieved between hospitals when national 
guidelines are issued. However, educational or other interventions may be needed, because 
significant differences in the treatment of bronchiolitis still existed, even between the university 
hospitals in our study, after implementing the national guidelines.  
The main strength of the study was that the results were based on real consumption figures at the 
different paediatric units of the four university hospitals and the figures were obtained from the 
hospital pharmacies. However, the study had two main limitations. Firstly, no data was available to 
indicate why the racemic adrenaline was given to the patients, namely specific diseases and 
indications. We only estimated that most of the inhalations on the paediatric infection wards were 
given to bronchiolitis patients. Croup very rarely needs in-patient treatment in hospital (27) and 
patients with asthma are hospitalised less than earlier and those hospitalised with severe asthma 
are usually treated in an intensive care unit (28). In any case racemic adrenaline is only a rescue 
therapy for severe asthma and it is needed very rarely. Secondly, the figures were only obtained 
from four university hospitals and the use of racemic adrenaline in secondary-level hospitals as 
well as in out-patient clinics, remains unclear. However, the hospitals we studied covered more 
than 30% of the child population in Finland. 
CONCLUSION 
We found some evidence that the 2014 Finnish evidence-based clinical care guidelines on the 
treatment of bronchiolitis had an impact on the everyday clinical care of children with regard to 
reducing the use of racemic adrenaline. They also had some impact on the amount of nursing time 
spent preparing and administering this treatment and reduced the already modest drugs costs. 
Future studies should focus on the impact that evidence-based current care guidelines have on 
children, including assessing cost effectiveness. Maybe such monitoring should be part of 
producing and updating any guidelines. 
Abbreviations  
PICU, paediatric intensive care unit 
References: 
1. Mecklin M, Hesselmar B, Qvist E, Wennergren G, Korppi M. Diagnosis and treatment of
bronchiolitis in Finnish and Swedish children’s hospitals. Acta Paediatr 2014;103:946–50.
2. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al.
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.
Pediatrics 2014;134:e1474-1502.
3. National Institute for Health and Care Excellence. Bronchiolitis : diagnosis and management
of bronchiolitis in children. Http://WwwNiceOrgUk/Guidance/Ng9 [Internet]. 2015 [cited 2017
Oct 12];1–301. Available from: https://www-ncbi-nlm-nih-gov.helios.uta.fi/pubmed/26065055
4. Angoulvant F, Bellêttre X, Milcent K, Teglas JP, Claudet I, Le Guen CG, et al. Effect of
nebulized hypertonic saline treatment in emergency departments on the hospitalization rate
for acute bronchiolitis: A randomized clinical trial. JAMA Pediatr 2017;171:e171333.
5. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al.
Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane
database Syst Rev 2013;6:CD004878.
6. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane database Syst Rev
2014;6:CD001266.
7. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute
bronchiolitis: Systematic review and meta-analysis. BMC Pulm Med 2015;15:148.
8. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al. Epinephrine and
dexamethasone in children with bronchiolitis. N Engl J Med 2009;360:2079–89.
9. Skjerven HO, Hunderi JO, Brugmann-Pieper SK, Brun AC, Engen H, Eskedal L, et al.
Racemic adrenaline and inhalation strategies in acute bronchiolitis. N Engl J Med
2013;368:2286–93.
10. Tapiainen T, Aittoniemi J, Immonen J, Jylkka H, Meinander T, Nuolivirta K, et al. Finnish
guidelines for the treatment of laryngitis, wheezing bronchitis and bronchiolitis in children.
Acta Paediatr 2016;105:44–9.
11. Giguère A, Légaré F, Grimshaw J, Turcotte S, Fiander M, Grudniewicz A, et al. Printed
educational materials: effects on professional practice and healthcare outcomes. In:
Cochrane Database of Systematic Reviews [Internet] 2012 [cited 2018 Jan 21]. p.
CD004398.
12. Breakell R, Thorndyke B, Clennett J, Harkensee C. Reducing unnecessary chest X-rays,
antibiotics and bronchodilators through implementation of the NICE bronchiolitis guideline.
EurJ Pediatr 2017; 177: 47-51.
13. Parikh K, Hall M, Teach SJ. Bronchiolitis management before and after the AAP guidelines.
Pediatrics 2014;133:1-7.
14. Register for Infectious Diseases, Institute of Health and Well-being, Finland [Internet] [cited
2018 Apr 15]. Available from: https://thl.fi/en/web/infectious-diseases.
15. Statistics on wellfare and health in Finland [Internet] [cited 2018 Feb 25]. Available from
https://www.sotkanet.fi/en/index.
16. Ralston S, Garber M, Narang S, Shen M, Pate B, Pope J, et al. Decreasing unnecessary
utilization in acute bronchiolitis care: results from the value in inpatient pediatrics network. J
Hosp Med 2013;8:25–30.
17. McCulloh RJ, Smitherman SE, Koehn KL, Alverson BK. Assessing the impact of national
guidelines on the management of children hospitalized for acute bronchiolitis. Pediatr
Pulmonol 2014;49:688–94.
18. Johnson LW, Robles J, Hudgins A, Osburn S, Martin D, Thompson A. Management of
bronchiolitis in the emergency department: impact of evidence-based guidelines? Pediatrics
2013;131 Suppl:103.
19. Florin TA, Byczkowski T, Ruddy RM, Zorc JJ, Test M, Shah SS. Variation in the
management of infants hospitalized for bronchiolitis persists after the 2006 American
Academy of Pediatrics bronchiolitis guidelines. J Pediatr 2014;165:786-92.e1.
20. Elenius V, Bergroth E, Koponen P, Remes S, Piedra PA, Espinola JA, et al. Marked
variability observed in inpatient management of bronchiolitis in three Finnish hospitals. Acta
Paediatr 2017;106:1512–8.
21. Sangrador CO, de Dios JG, of the aBREVIADo Project (Bronchiolitis--Study of Variability
Adequacy, Adherence). Management of acute bronchiolitis in emergency wards in Spain:
variability and appropriateness analysis (aBREVIADo Project). Eur J Pediatr
2012;171:1109–19.
22. Macias CG, Mansbach JM, Fisher ES, Riederer M, Piedra PA, Sullivan AF, et al. Variability
in inpatient management of children hospitalized with bronchiolitis. Acad Pediatr
2015;15:69–76.
23. Akenroye AT, Baskin MN, Samnaliev M, Stack AM. Impact of a bronchiolitis guideline on ED
resource use and cost: a segmented time-series analysis. Pediatrics 2014;133:e227-34.
24. Mittal V, Darnell C, Walsh B, Mehta A, Badawy M, Morse R, et al. Inpatient
bronchiolitis5guideline implementation and resource utilization. Pediatrics 2014;133:e730-7.
25. Clements H, Stephenson T, Gabriel V, Harrison T, Millar M, Smyth A, et al. Rationalised
prescribing for community acquired pneumonia: A closed loop audit. Arch Dis Child
2000;83:320–4.
26. Ralston SL, Garber MD, Rice-Conboy E, Mussman GM, Shadman KA, Walley SC, et al. A
Multicenter Collaborative to Reduce Unnecessary Care in Inpatient Bronchiolitis. Pediatrics
2016;137:e20150851.
27. Tyler A, McLeod L, Beaty B, Juarez-Colunga E, Birkholz M, Hyman D, et al. Variation in
Inpatient Croup Management and Outcomes. Pediatrics 2017;139:e20163582.
28. Kivistö JE, Protudjer JLP, Karjalainen J, Bergström A, Korppi M. Trends in paediatric
asthma hospitalisations - differences between neighbouring countries. Thorax 2018;73:185–
7.
Table 1. The number of doses of racemic adrenaline (2.25%, 0.5ml inhalation solution) delivered 
from the pharmacies to the paediatric department in the four Finnish university hospitals. The data 
are presented separately for the emergency room (ER), paediatric infectious diseases ward (ward) 
and paediatric intensive care unit (PICU) of each hospital during 2012-2016.  
*Total doses of racemic adrenaline (racepinephrine) and doses per 10,000 children aged less than
16 years. ^ The ER costs were included in the ward costs and could not be obtained separately. 
Hospital Unit 2012 2013 2014 2015 2016 
Tampere Total* 3,295 366 3,498 388 2,460 270 780 85 773 85 
ER 870 738 630 210 293 
Ward 2,125 2,400 1,350 450 330 
PICU 300 360 480 120 150 
Oulu Total* 485 56 672 77 648 74 537 61 650 74 
ER^ - - - - - 
Ward 230 291 240 248 325 
PICU 155 251 270 185 210 
Turku Total* 1,135 144 689 88 560 71 490 63 326 42 
ER 280 417 110 30 146 
Ward 290 120 330 310 145 
PICU 270 150 60 116 30 
Kuopio Total* 2,283 846 2,745 1,035 2,333 880 1,919 734 1,373 532 
ER 367 286 324 260 270 
Ward 1,625 1,894 1,709 1,305 920 
PICU 79 55 25 23 53 
Table 2. The costs of racemic adrenaline (racepinephrine 2.25% 0.5ml inhalation solution) and 
working time of nurses (in hours) used for administering nebulisation in four university hospitals in 
Finland during the years 2012-2016. In Finland, the regular working time of nurses is 38.25 hours 
per week. 
. 
2012 2013 2014 2015 2016 
Tampere 
costs (€) 
working time (h) 
7,579 
1,263 
8,045 
1,341 
5,658 
943 
1,794 
299 
1,778 
296 
Oulu 
costs (€) 
working time (h) 
1,116 
186 
1,546 
258 
1,490 
248 
1,235 
206 
1,495 
249 
Turku 
costs (€) 
working time (h) 
2,611 
435 
1,585 
264 
1,288 
215 
1,127 
188 
750 
125 
Kuopio 
costs (€) 
working time (h) 
5,251 
875 
6,314 
1,052 
5,366 
894 
4,414 
736 
3,158 
526 
Supplementary Figure 1. The annual consumption of racemic adrenaline in four university 
hospitals in Finland in years 2012-2016 (racepinephrine 2.25% 0.5ml doses). The lower graph 
shows the consumption adjusted to doses per 10,000 children under the age of 16 years.  
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